Trials / Unknown
UnknownNCT05802862
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
A Multi-center, Randomized, Open, Phase III Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared Efficacy and Safety With Insulin Degludec/Insulin Aspart(Ryzodeg) in Chinese Subjects With Type 2 Diabetes
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 408 (estimated)
- Sponsor
- Sunshine Lake Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if Insulin Degludec/Insulin Aspart (22011) compared to Insulin Degludec/Insulin Aspart (Ryzodeg) is similar in safety and effect in participants with type 2 diabetes (T2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin Degludec and Insulin Aspart | administered subcutaneously, once a day |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2023-12-01
- Completion
- 2024-03-01
- First posted
- 2023-04-07
- Last updated
- 2023-04-07
Source: ClinicalTrials.gov record NCT05802862. Inclusion in this directory is not an endorsement.